These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 28572460)
1. Capecitabine Extends Survival for Biliary Tract Cancer. Cancer Discov; 2017 Jul; 7(7):OF1. PubMed ID: 28572460 [TBL] [Abstract][Full Text] [Related]
2. Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials. Belkouz A; Wilmink JW; Haj Mohammad N; Hagendoorn J; de Vos-Geelen J; Dejong CHC; Homs MYV; Groot Koerkamp B; van Gulik TM; van Oijen MGH; Punt CJA; Klümpen H Crit Rev Oncol Hematol; 2020 Jul; 151():102975. PubMed ID: 32464483 [TBL] [Abstract][Full Text] [Related]
3. Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma. Cereda S; Milella M; Cordio S; Leone F; Aprile G; Galiano A; Mosconi S; Vasile E; Santini D; Belli C; Auriemma A; Novarino A; Vaccaro V; Martines C; Marino D; Lutrino SE; Palazzo V; Reinach B; Aldrighetti L; Reni M Cancer Chemother Pharmacol; 2016 Jan; 77(1):109-14. PubMed ID: 26659366 [TBL] [Abstract][Full Text] [Related]
4. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Lamarca A; Edeline J; McNamara MG; Hubner RA; Nagino M; Bridgewater J; Primrose J; Valle JW Cancer Treat Rev; 2020 Mar; 84():101936. PubMed ID: 31986437 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials. Nara S; Esaki M; Ban D; Takamoto T; Shimada K; Ioka T; Okusaka T; Ishii H; Furuse J Jpn J Clin Oncol; 2020 Dec; 50(12):1353-1363. PubMed ID: 33037430 [TBL] [Abstract][Full Text] [Related]
6. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. Rizzo A; Brandi G Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):483-485. PubMed ID: 33307876 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives. Akhoundova Sanoyan D; McNamara MG; Lamarca A; Valle JW Curr Opin Oncol; 2020 Jul; 32(4):364-369. PubMed ID: 32541326 [TBL] [Abstract][Full Text] [Related]
8. ADJUBIL: phase II study of adjuvant immunotherapy with STRIDE regimen with/without capecitabine in biliary tract cancers. Goetze T; Gonzalez-Carmona MA; Kochen L; Agaoglu NB; Al-Batran SE; Habibzada T; Pons M; Brunner M; Ettrich TJ; Köhne CH; Roderburg C; Modest D Future Oncol; 2024 Feb; 20(6):307-315. PubMed ID: 38410920 [TBL] [Abstract][Full Text] [Related]
9. Network meta-analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence. Salani F; Vetere G; Rossini D; Genovesi V; Carullo M; Bartalini L; Massa V; Bernardini L; Caccese M; Cesario S; Graziani J; Grelli G; Mangogna F; Vivaldi C; Masi G; Fornaro L Liver Int; 2024 Oct; 44(10):2763-2772. PubMed ID: 39072988 [TBL] [Abstract][Full Text] [Related]
10. Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer. Jung JH; Lee HS; Jo JH; Cho IR; Chung MJ; Bang S; Park SW; Song SY; Park JY Chemotherapy; 2017; 62(6):361-366. PubMed ID: 28848173 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions. Rizzo A; Brandi G Cancer Treat Res Commun; 2021; 27():100334. PubMed ID: 33592563 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant and neoadjuvant chemotherapy for biliary tract cancer: a review of randomized controlled trials. Nakachi K; Gotohda N; Hatano E; Nara S; Takahashi S; Kawamoto Y; Ueno M Jpn J Clin Oncol; 2023 Nov; 53(11):1019-1026. PubMed ID: 37599063 [TBL] [Abstract][Full Text] [Related]
13. The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection. Kim YS; Jeong CY; Song HN; Kim TH; Kim HJ; Lee YJ; Hong SC Chin J Cancer; 2017 Jan; 36(1):9. PubMed ID: 28086990 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials. Caparica R; Bruzzone M; Hachem GE; Ceppi M; Lambertini M; Glasberg J; de Azambuja E; Van Laethem JL; Hendlisz A Crit Rev Oncol Hematol; 2020 May; 149():102940. PubMed ID: 32252001 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602 [TBL] [Abstract][Full Text] [Related]
16. Capecitabine: Still a Standard Option in the Adjuvant Setting of Biliary Tract Cancer? Edeline J; Malka D J Clin Oncol; 2022 Nov; 40(31):3667-3668. PubMed ID: 35786978 [No Abstract] [Full Text] [Related]
17. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. Bridgewater J; Fletcher P; Palmer DH; Malik HZ; Prasad R; Mirza D; Anthony A; Corrie P; Falk S; Finch-Jones M; Wasan H; Ross P; Wall L; Wadsley J; Evans TR; Stocken D; Stubbs C; Praseedom R; Ma YT; Davidson B; Neoptolemos J; Iveson T; Cunningham D; Garden OJ; Valle JW; Primrose J; J Clin Oncol; 2022 Jun; 40(18):2048-2057. PubMed ID: 35316080 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant treatments in biliary tract cancer: an analysis based on restricted mean survival time. Messori A; Bartoli L; Trippoli S Dig Liver Dis; 2020 Oct; 52(10):1208-1209. PubMed ID: 32505564 [No Abstract] [Full Text] [Related]
19. The Landmark Series: Gallbladder Cancer. Gamboa AC; Maithel SK Ann Surg Oncol; 2020 Aug; 27(8):2846-2858. PubMed ID: 32474816 [TBL] [Abstract][Full Text] [Related]
20. [Adjuvant treatment of biliary tract cancers: Who and how?]. Edeline J Bull Cancer; 2020 Jan; 107(1):48-53. PubMed ID: 31980143 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]